PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031

Phase 1

Completed

Conditions: Prostatic Hyperplasia
Urinary Bladder, Overactive
Erectile Dysfunction

Interventions: Drug: UK369,003
Drug: sildenafil
Drug: sildenafil matching placebo

First Posted Date: 2008-12-25

Last Posted Date: 2008-12-25

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT00814736

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: CP-690,550
Drug: Placebo

First Posted Date: 2008-12-24

Last Posted Date: 2013-01-18

Lead Sponsor: Pfizer

Target Recruit Count: 611

Registration Number: NCT00814307

Locations: 🇺🇦
Pfizer Investigational Site, Vinnitsa, Ukraine

A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PF-04171327
Drug: Prednisolone
Drug: Placebo
Drug: Placebo Solution
Drug: PF-04171327 Tablet

First Posted Date: 2008-12-22

Last Posted Date: 2009-08-12

Lead Sponsor: Pfizer

Target Recruit Count: 78

Registration Number: NCT00812825

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis

Phase 2

Terminated

Conditions: Ankylosing Spondylitis

Interventions: Drug: ARRY-371797, p38 inhibitor; oral
Drug: Placebo; oral

First Posted Date: 2008-12-19

Last Posted Date: 2020-10-19

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT00811499

Locations: 🇺🇸
Westroads Medical Group, Omaha, Nebraska, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 9 locations

Safety And Efficacy Of Rifabutin In HIV Patients

Completed

Conditions: Non-tuberculous Mycobacterial Diseases
Tuberculosis
Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections

Interventions: Drug: rifabutin

First Posted Date: 2008-12-18

Last Posted Date: 2019-08-02

Lead Sponsor: Pfizer

Target Recruit Count: 72

Registration Number: NCT00810446

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

Phase 3

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Sitaxsentan

First Posted Date: 2008-12-18

Last Posted Date: 2012-04-24

Lead Sponsor: Pfizer

Target Recruit Count: 1192

Registration Number: NCT00811018

Locations: 🇬🇧
Pfizer Investigational Site, Newcastle, United Kingdom

Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients

Completed

Conditions: Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
Tuberculosis

Interventions: Drug: rifabutin

First Posted Date: 2008-12-18

Last Posted Date: 2019-03-07

Lead Sponsor: Pfizer

Target Recruit Count: 628

Registration Number: NCT00810407

Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects

Phase 2

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: Open
Drug: Nifedipine

First Posted Date: 2008-12-18

Last Posted Date: 2023-07-06

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT00810732

Locations: 🇬🇧
Clinical Research Centre and Pharmacology Unit, Edinburgh, Scotland, United Kingdom
🇬🇧
the University of Edinburgh, Western General Hospital, Department of Medical Sciences, Edinburgh, Scotland, United Kingdom

Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

Phase 1

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: PF-04878691 3mg
Drug: PF-04878691 6mg
Drug: PF-04878691 9mg

First Posted Date: 2008-12-18

Last Posted Date: 2009-12-01

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00810758

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: SKI-606 (Bosutinib)

First Posted Date: 2008-12-18

Last Posted Date: 2016-06-28

Lead Sponsor: Pfizer

Target Recruit Count: 63

Registration Number: NCT00811070

Locations: 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵
Tohoku University Hospital, Sendai-city, Miyagi, Japan
🇯🇵
Toyohashi Municipal Hospital, Aichi, Japan

and more 20 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy